GCTKGlucoTrack Inc

Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 28.6% to $0.64 during Thursday's after-market session. The company's market cap stands at $3.3 million. Stereotaxis (AMEX:STXS) stock increased by 8.51%read more...

Several small-cap companies announced developments that could reshape their long-term business models, while others reported operational progress that investors will be watching closely over the coming quarters. $JTAI, $XERI, $PMI, $VTAK, $GCTK, $LCID

Glucotrack Inc. shares jumped 69.27% after hours as investors reacted to the company's newly allowed U.S. patent for its glucose monitoring.read more...

Advancements in diabetes technology continue to accelerate as companies race to improve patient outcomes and quality of life. Continuous glucose monitoring (CGM) has become one of the fastest-growing segments in healthcare, but limitations around wearable devices, sensor longevity, and accuracy still leave room for innovation. The next frontier may lie in implantable solutions designed to deliver more precise, real-time data without the burden of external hardware.Shares of Glucotrack, Inc. (NASDAQ: GCTK) are climbing sharply Friday morning after the company announced it is preparing to ...

Advancements in diabetes technology continue to accelerate as companies race to improve patient outcomes and quality of life. Continuous glucose monitoring (CGM) has become one of the fastest-growing segments in healthcare, but limitations around wearable devices, sensor longevity, and accuracy still leave room for innovation. The next frontier may lie in implantable solutions designed to deliver more precise, real-time data without the burden of external hardware.Shares of Glucotrack, Inc. (NASDAQ: GCTK) are climbing sharply Friday morning after the company announced it is preparing to ...

A new wave of healthcare innovation, powered by artificial intelligence, next-generation biologics, and shifting regulatory pathways, is colliding with market dynamics to create both breakthrough potential and high-volatility trading setups. $ARTL, $TGNT, $ADMA, $RCKT, $LTRN, $GCTK

Glucotrack said it has achieved critical operational milestones in developing its continuous blood glucose monitoring technology.

The company has received patents for its continuous blood glucose monitoring system.

Glucotrack announced a new financing arrangement with Sixth Borough Capital Fund LP on Thursday.